Bristol Myers Squibb Reports Two-Year Data Showing Durable Sotyktu Efficacy in Psoriatic Arthritis Bristol Myers Squibb (NYSE: BMY) announced positive two-year results from the Phase 3 POETYK PsA-2 study and…
Novartis’ Cosentyx Receives Positive CHMP Opinion for Polymyalgia Rheumatica in Europe Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
Roche’s Ocrevus Gains Positive CHMP Opinion for Pediatric Multiple Sclerosis in Europe Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
Roche Opens Innovation Center Boston to Expand Cardiovascular, Renal and Metabolism Research Roche (SIX: RO, ROP; OTCQX: RHHBY) has officially opened the Roche Genentech Innovation Center Boston, marking a significant…
Roche’s Lunsumio Combination Meets Primary Endpoint in Phase III CELESTIMO Trial for Relapsed or Refractory Follicular Lymphoma Roche has announced positive topline results from the Phase III CELESTIMO study evaluating…
Merck Launches “Your Hive of Whole Health” Program to Support Whole-Person Well-Being for People Living With HIV Merck (NYSE: MRK), known as MSD outside the United States and Canada, has…
AbbVie Presents New VRAYLAR Data Highlighting Real-World Outcomes in Depression and Bipolar I Disorder AbbVie (NYSE: ABBV) has presented new data for VRAYLAR® (cariprazine) at Psych Congress 2026 in New…
Novo Nordisk’s FREHEMGO Receives Positive CHMP Opinion for Haemophilia A Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)…
Lilly to Present New Cardiometabolic Data on Foundayo, Retatrutide and EloraTZP at EASD 2026 Eli Lilly and Company (NYSE: LLY), the manufacturer of Zepbound® (tirzepatide), Mounjaro® (tirzepatide) and Foundayo® (orforglipron),…
IMPACT Therapeutics’ Senaparib Receives Positive EMA CHMP Opinion for Ovarian Cancer Maintenance Treatment IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on developing targeted anti-cancer therapies based on synthetic lethality…
Largest Lung Cancer MRD Study Demonstrates Signatera™’s Strong Prognostic Value Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, has announced new clinical data presented…
LEO Pharma Gains FDA Priority Review for Dersimelagon NDA Following Acquisition of Global Rights LEO Pharma, a global leader in medical dermatology, has announced two significant developments for dersimelagon, an…